<DOC>
	<DOC>NCT01359969</DOC>
	<brief_summary>This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.</brief_summary>
	<brief_title>Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>From 2 up to and including 13 years of age Clinical and laboratory confirmed diagnosis of HAE (baseline C1INH activity &lt;50% of normal) Signed written informed consent (parental permission) signed by the legal guardian(s) Clinical symptoms of an acute HAE attack Onset of eligible symptoms within 5 hours from the moment at which medical evaluation to determine eligibility has occurred Attack severity moderate or greater, as rated by the investigator A diagnosis of acquired C1INH deficiency (AAE) A medical history of allergy to rabbits or rabbitderived products or positive antirabbit epithelium (dander) IgE test</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>HAE</keyword>
	<keyword>Angioedema</keyword>
	<keyword>Recombinant C1 Inhibitor</keyword>
	<keyword>rhC1INH</keyword>
	<keyword>Pediatrics</keyword>
</DOC>